Skip to main content

Advertisement

SpringerLink
Log in

Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The effectiveness of reduced-intensity conditioning allogeneic stem cell transplantation (allo- RIC) compared with high-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) in Hodgkin’s disease (HD) and in non-Hodgkin’s lymphoma (NHL) patients remains poorly defined. The purpose of the study was to demonstrate the usefulness of auto-SCT or allo-SCT, employing a RIC regimen in refractory or relapsed NHL or HD patients. We analyzed the outcome of 71 patients with advanced disease. Twenty-three NHL and 14 HD patients received an allo-RIC using fludarabine, cyclophosphamide, and low-dose busulfan as the conditioning regimen. Sixteen NHL and 18 HD patients received auto-SCT using cyclophosphamide and etoposide as conditioning regimen. All hematopoietic stem cells products were not cryopreserved and the majority of grafts were done on an outpatient basis, including conditioning and post-stem cell infusion care (auto-SCT, 62% and allo-RIC procedure, 91%). The median OS was 45.5 months for the allo-RIC recipients and 53.3 months for auto-SCT recipients. Acute/chronic GVHD incidence in NHL and HL groups was 38%/31% and 14%/7%, respectively. We found no significant difference in overall survival between allo-RIC group and auto-SCT group for NHL patients (P = 0.43) but better OS was observed for auto-SCT group than for allo-SCT group in HL patients (P < 0.001). The relapse rate was higher in autografted patients, both in NHL and HD. Both auto-SCT and allo-RIC appear to be valid treatments for poor-risk patients with relapsed or refractory lymphoma who could not otherwise be cured with conventional salvage regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bellesi G, Rigacci L, Longo G, Alterini R, Bernardi F, Messori A et al (2000) Treatment of large cell lymphoma with the Fi2 regimen (doxorubicin, vincristinem cyclophosphamide, bleomycin and prednisone): 25-year experience. Oncol Rep 7:891–896

    CAS  PubMed  Google Scholar 

  2. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D et al (2000) Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin´s disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 18:972–980

    CAS  PubMed  Google Scholar 

  3. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F et al (1997) Outcome of patients with Hodgkin’s disease failing after primary MOPP–ABVD. J Clin Oncol 15:528–534

    CAS  PubMed  Google Scholar 

  4. Lazarus HM, Loberiza FR Jr, Armitage ZMJ, JO BKK, Bashey A, Bolwell BJ et al (2001) Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 27:387–396

    Article  CAS  PubMed  Google Scholar 

  5. Akpek G, Ambider RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB et al (2001) Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 19:4314–4321

    CAS  PubMed  Google Scholar 

  6. Rapaport AP, Lifton R, Constine LS, Duerst RE, Abboud CN, Liesveld JL et al (1997) Autotransplantation for relapsed or refractory non-Hodgkin´s lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 19:883–890

    Article  Google Scholar 

  7. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW (2006) Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non Hodgkin’s lymphoma. Biol Blood Marrow Transplant 12:770–777

    Article  Google Scholar 

  8. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA et al (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97:616–623

    Article  CAS  PubMed  Google Scholar 

  9. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A et al (2006) Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 12:1065–1072

    Article  PubMed  Google Scholar 

  10. Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991) Evidence of a graft versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649–653

    CAS  PubMed  Google Scholar 

  11. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, Ruiz de Elvira C et al (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310–4316

    Article  CAS  PubMed  Google Scholar 

  12. Tomblyn M, Brunstein C, Burns LJ, Miller JS, MacMillan M, DeFor TE et al (2008) Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 14:538–545

    Article  PubMed  Google Scholar 

  13. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 12:172–183

    Article  PubMed  Google Scholar 

  14. Porter DL, Stadtmauer EA, Lazarus HM (2003) GVHD: graft-versus-host-disease or graft-versus-Hodgkin’s disease? An old acronym with new meaning. Bone Marrow Transplant 31:739–746

    Article  CAS  PubMed  Google Scholar 

  15. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD et al (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21 years Seattle experience. J Clin Oncol 11:2342–2350

    CAS  PubMed  Google Scholar 

  16. Kessinger A, Armitage JO, Landmark JD (1988) Autologus peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 71:723–727

    CAS  PubMed  Google Scholar 

  17. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE (2000) Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 25:131–133

    Article  PubMed  Google Scholar 

  18. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O (2002) Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 87:894–896

    PubMed  Google Scholar 

  19. Ruiz-Argüelles A (1992) Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 50:735–743

    Google Scholar 

  20. Ruiz-Delgado GJ, Gutiérrez-Riveroll KI, Gutiérrez-Aguirre CH, Gómez-Almaguer D, Eyzaguirre-Zapata R, Priesca-Marin M et al (2009) A single apheresis procedure in the donor may be enough to complete an allograft using the “Mexican Method” of non-ablative allografting. Blood Transfus 7:127–131

    PubMed  Google Scholar 

  21. Ruiz-Argüelles A, Orfao A (1996) Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles GJ, San-Miguel JF (eds) Actualización en Leucemias. Editorial Médica Panamericana, México City, pp 79–82

    Google Scholar 

  22. Giralt S, Estey E, Albitar M, Van Besien K, Rondón G, Anderlini P et al (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531–4536

    CAS  PubMed  Google Scholar 

  23. Yam PY, Petz LD, Knowlton RG, Wallace RB, Stock AD, de Lange G et al (1987) Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 43:399–407

    Article  CAS  PubMed  Google Scholar 

  24. Carbone PP, Kaplan HS, Musshogg K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 31:1860–1861

    CAS  PubMed  Google Scholar 

  25. Shulman HM, Sullivan KM, Weiden PL (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217

    Article  CAS  PubMed  Google Scholar 

  26. Gutierrez-Aguirre CH, Cantú-Rodríguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-González O, Jaime-Pérez JC et al (2007) Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology 12(3):193–197

    Article  CAS  PubMed  Google Scholar 

  27. Svahn B-M, Bjurman B, Myrback KE, Aschan J, Rindgen O (2000) Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial. Bone Marrow Transplant 26:1057–1060

    Article  CAS  PubMed  Google Scholar 

  28. McSweeney PA, Niederwiser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390–3400

    Article  CAS  PubMed  Google Scholar 

  29. Gutierrez-Aguirre CH, Gomez-Almaguer D, Cantu-Rodríguez OG, Gonzalez-Llano O, Jaime-Perez JC, Herena-Perez S, Manzano CA et al (2007) Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant 40(6):535–539

    Article  CAS  PubMed  Google Scholar 

  30. Cantú-Rodríguez OG, Jaime-Perez JC, Gutierrez-Aguirre CH, González-Llano O, Mancias-Guerra C, Tarin-Arzaga LC et al (2007) Outpatient allografting using non-myeloablative conditioning: the Mexican experience. Bone Marrow Transplant 40(2):119–123

    Article  PubMed  Google Scholar 

  31. Bertz H, Illerhaus G, Veelken H, Finke J (2002) Allogeneic hematopoietic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 13:135–139

    Article  CAS  PubMed  Google Scholar 

  32. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al (2000) In vivo CAMPATH-1H prevents graft-versus host disease following nonmyeloablative stem cell transplantation. Blood 96:2419–2425

    CAS  PubMed  Google Scholar 

  33. Gómez-Almaguer D, Ruiz-Argüelles GJ, González-Llano O, González-Llano O, Gutiérrez-Aguirre H, Cantú-Rodríguez O et al (2008) Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 14(1):10–15

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Hematología del Hospital Universitario U.A.N.L, Monterrey, Nuevo León, México

    Cesar Homero Gutiérrez-Aguirre, Olga Graciela Cantú-Rodríguez, Oscar González-Llano, José Carlos Jaime-Pérez, Fernando García-Rodríguez, José Luis Herrera-Garza & David Gómez-Almaguer

  2. Centro de Hematología y Medicina Interna de Puebla, Puebla, México

    Guillermo Ruiz-Argüelles & Avril López-Otero

Authors
  1. Cesar Homero Gutiérrez-Aguirre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guillermo Ruiz-Argüelles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olga Graciela Cantú-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oscar González-Llano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. José Carlos Jaime-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fernando García-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Avril López-Otero
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. José Luis Herrera-Garza
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David Gómez-Almaguer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cesar Homero Gutiérrez-Aguirre.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gutiérrez-Aguirre, C.H., Ruiz-Argüelles, G., Cantú-Rodríguez, O.G. et al. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Ann Hematol 89, 1045–1052 (2010). https://doi.org/10.1007/s00277-010-0986-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-0986-1

Keywords

Search

Navigation